This meeting featured the HESI Genomics Committee’s first public release of results from its four 2005-2007 research programs. The presentations covered: a) insights into ‘noisy’ and ‘quiet’ baseline gene expression as evaluated in a novel database of control rodent microarray data from liver/kidney; b) results from a 6 week rodent cardiotoxicity study designed by the Committee to explore the relationship between traditional toxicity measures (e.g., histopathology and clinical chemistry) and more recent mechanistic/toxicity tools (e.g., gene microarray and cardiac troponin data); c) outputs from a multi-lab pilot studying using RT-PCR and microarray to identify gene sets capable of distinguishing direct and in-direct acting genotoxins; and finally, d) a report on the variation in applications of and perceptions about microarray technologies in different sectors and job categories according to the Committee’s online survey of over 100 scientists. Day 2 of the meeting focused on identification of new research priorities for the Committee for 2008. The meeting was held at the Westin Washington Hotel and was open to the public.
The Committee represents a body of more than 22 private sector companies in the chemical and pharmaceutical industries, government scientists, and academics from the U.S., Japan, and Europe. The Committee has collaboratively designed, executed, and interpreted the studies to be presented at this session. As such, the outcomes represent the perspectives and expertise of a broad range of participating scientists and are anticipated to help build consensus around the meaningful application of genomic data.
The meeting will featured the HESI Genomics Committee’s first public release of results from its four 2005-2007 research programs. The presentations covered: a) insights into ‘noisy’ and ‘quiet’ baseline gene expression as evaluated in a novel database of control rodent microarray data from liver/kidney; b) results from a 6 week rodent cardiotoxicity study designed by the Committee to explore the relationship between traditional toxicity measures (e.g., histopathology and clinical chemistry) and more recent mechanistic/toxicity tools (e.g., gene microarray and cardiac troponin data); c) outputs from a multi-lab pilot studying using RT-PCR and microarray to identify gene sets capable of distinguishing direct and in-direct acting genotoxins; and finally, d) a report on the variation in applications of and perceptions about microarray technologies in different sectors and job categories according to the Committee’s online survey of over 100 scientists. Day 2 of the meeting focused on identification of new research priorities for the Committee for 2008.
To download a copy of the workshop agenda, click here.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.